Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study
1997

Combined Treatment for Advanced Pancreatic Cancer

Sample size: 32 publication Evidence: moderate

Author Information

Author(s): FJ Prott, K Schonekaes, P Preusser, K Ostkamp, W Wagner, 0 Micke, R Potter, U Sulkowski, C Rube, T Berns, N Willich

Primary Institution: University of Munster, Medical School, Monster, Germany

Hypothesis

Can combined modality treatment with accelerated radiotherapy and chemotherapy improve survival in patients with locally advanced inoperable pancreatic cancer?

Conclusion

The combined treatment of accelerated hyperfractionated radiotherapy and chemotherapy is feasible and improves median survival time for patients with locally advanced pancreatic cancer.

Supporting Evidence

  • The median survival time for patients was 12.7 months, compared to 3-7 months after palliative surgery.
  • The median progression-free interval was 6.6 months.
  • Severe side effects occurred in 9.3% of patients.

Takeaway

Doctors tried a new way to treat patients with a tough kind of pancreatic cancer, and it helped them live longer than usual.

Methodology

Patients received hyperfractionated radiotherapy and chemotherapy with 5-fluorouracil and folinic acid over a period of less than 3 weeks.

Limitations

The study had a small sample size and was a feasibility study, which may limit the generalizability of the results.

Participant Demographics

11 women and 21 men, median age 62.3 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication